Our History

1977:
Launched Krestin (Poly-saccharide-K) in Japan to treat gastrointestinal, lung and breast cancer

1985:
Launched the first natural-type interferon beta preparations for brain tumour and skin cancer in Japan

1995:
Received approval of irinotecan, the first chemotherapy to demonstrate survival benefits in colorectal cancer1

2012:
Launched denosumab in Japan for treatment of bone complications of multiple myeloma and bone metastases of solid tumours

2020:
>20 compounds in development directed at a range of diseases with unmet medical needs, with a focus on ADC technology

2021:
In January 2021, trastuzumab deruxtecan received EMA approval for HER2-positive metastatic breast cancer in the EU2

2022:
Trastuzumab deruxtecan received approval for second line therapy in the EU3

We have more than 40 years of experience in cancer treatment, innovations and research!

References

1 Douillard JY, Clin Col Can. 2005,; 5 (S1): S34-S37.

2 Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens SmPC at www.ema.europa.eu.

3 Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens. SmPC at www.ema.europa.eu

back to top

User login

Enter your username and password here in order to log in on the website